Windtree Therapeutics

Contributing Author

Recent Articles by Windtree Therapeutics

13 hours	Windtree Therapeutics Stockholders Approve Key Proposals for Revenue and Profit Generation at the Special Stockholder Meeting WINT -33.15% GlobeNewswire
Aug-11	Windtree Announces Istaroxime has been Chosen for a Plenary Session Presentation at the Heart Failure Society of America 2025 WINT GlobeNewswire
Aug-05	Windtree Announces Istaroxime Phase 2 Interim Analysis in SCAI Stage C Cardiogenic Shock Patients WINT GlobeNewswire
Jul-29	Windtree Therapeutics Announces Large Reduction of Preferred Series C and D Shares Outstanding by Conversion and Redemption WINT GlobeNewswire
Jul-24	Windtree Therapeutics Announces Up To $520 Million in New Funding to Amplify BNB Cryptocurrency Treasury Strategy WINT GlobeNewswire
Jul-22	Kraken and Windtree Therapeutics Announce Strategic Partnership for BNB Custody, Trading, and OTC Services WINT GlobeNewswire
Jul-16	Windtree To Launch BNB Crypto Treasury Strategy With Agreement For $60 Million Investment Led By Build And Build Corp. With Up To $140 Million More In Follow On Subscriptions WINT GlobeNewswire
Jul-02	Windtree Announces Issuance of Istaroxime Patent for the United States for Acute Heart Failure WINT GlobeNewswire
Jun-30	Windtree Announces Istaroxime Phase 2 Cardiogenic Shock Study Hits Enrollment Target for Planned Interim Analysis WINT GlobeNewswire
Jun-26	Windtree Advances Lower Cost Manufacturing of PHEXXI, Evofem's Hormone-Free, On-Demand Prescription Contraceptive Gel WINT GlobeNewswire
Jun-16	Windtree Announces Publication of Istaroxime Positive Phase 2 SEISMiC B Study WINT GlobeNewswire
Jun-11	Windtree Receives Offer for Its Preclinical Oncology Drug Candidate WINT GlobeNewswire
Jun-10	Windtree Announces Transformational Agreement to Acquire Revenue Generating Environmental Services Business WINT GlobeNewswire
Jun-03	Windtree Announces Plan for Cryptocurrency Treasury Policy WINT GlobeNewswire
May-22	Windtree Therapeutics Announces Istaroxime Cardiogenic Shock SCAI Stage C Phase 2 Study Planned Interim Analysis Results Targeted for July 2025 WINT GlobeNewswire
May-19	Windtree Therapeutics Announces Istaroxime Presentation at European Society of Cardiology Heart Failure Conference WINT GlobeNewswire
May-16	Windtree Therapeutics Reports First Quarter 2025 Financial Results and Provides Key Business Updates WINT GlobeNewswire
May-12	Windtree Therapeutics Announces Presentation of Preclinical Data on Istaroxime and a Selective SERCA2a Activator at the European Society of Cardiology Heart Failure Conference May 17, 2025 WINT GlobeNewswire
May-06	Windtree Announces Istaroxime Exclusivity and Intellectual Property Potential Strategy for US WINT GlobeNewswire
May-01	Windtree Announces Strategic Transaction to Drive Revenue Generation in Support of Ongoing Therapeutic Pipeline Development WINT GlobeNewswire

Windtree Therapeutics

Recent Articles by Windtree Therapeutics

Upgrade your FINVIZ experience